Publication | Closed Access

Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway

UrologyAkt PathwayAnti-prostate Cancer ActivityMedicineHormonal ReceptorPharmacotherapyAnti-cancer AgentProstatic DiseasePharmacologyTumor MicroenvironmentEndocrine-related CancerDrug Discovery